Abstract
Overview: Personalized treatment in cardiovascular diseases is an inevitable trend in practice. The VerifyNow test for assessing aspirin and clopidogrel response is a promising tool in terms of effectiveness and high availability.
Objective: To report the frequency of poor response to aspirin and clopidogrel in a population of patients undergoing percutaneous coronary intervention.
Method: A descriptive cross-sectional study, conducted from August 2022 to March 2023 at the Department of Interventional Cardiology, University Medical Center of Ho Chi Minh City
Results: Among 100 patients participating in the study, 9 patients did not respond to aspirin, 17 patients did not respond to clopidogrel. There were 3 patients who did not respond to both aspirin and clopidogrel.
Conclusion: VerifyNow is a quick and effective test in identifying groups that do not respond to aspirin and clopidogrel. Larger studies are needed to determine the role of the VerifyNow test in clinical practice.